Insider Selling: Phreesia, Inc. (NYSE:PHR) SVP Sells 11,616 Shares of Stock

Phreesia, Inc. (NYSE:PHR - Get Free Report) SVP David Linetsky sold 11,616 shares of the company's stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $29.70, for a total transaction of $344,995.20. Following the transaction, the senior vice president now directly owns 218,135 shares of the company's stock, valued at approximately $6,478,609.50. This represents a 5.06 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

David Linetsky also recently made the following trade(s):

• On Friday, February 7th, David Linetsky sold 300 shares of Phreesia stock. The shares were sold at an average price of $29.52, for a total transaction of $8,856.00.
• On Wednesday, February 5th, David Linetsky sold 720 shares of Phreesia stock. The shares were sold at an average price of $29.50, for a total transaction of $21,240.00.
• On Wednesday, January 29th, David Linetsky sold 500 shares of Phreesia stock. The stock was sold at an average price of $29.68, for a total transaction of $14,840.00.
• On Monday, January 27th, David Linetsky sold 11,685 shares of Phreesia stock. The stock was sold at an average price of $27.48, for a total transaction of $321,103.80.
• On Wednesday, December 18th, David Linetsky sold 24 shares of Phreesia stock. The stock was sold at an average price of $25.38, for a total transaction of $609.12.
• On Monday, December 16th, David Linetsky sold 35 shares of Phreesia stock. The stock was sold at an average price of $24.88, for a total transaction of $870.80.
• On Wednesday, December 11th, David Linetsky sold 11,853 shares of Phreesia stock. The stock was sold at an average price of $24.85, for a total transaction of $294,547.05.

Phreesia Stock Down 0.9 %

Shares of Phreesia stock traded down $0.27 on Friday, hitting $28.20. 500,095 shares of the company's stock traded hands, compared to its average volume of 364,321. The stock has a market cap of $1.64 billion, a P/E ratio of -19.18 and a beta of 0.96. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04. The firm's 50-day moving average is $27.29 and its 200 day moving average is $23.84. Phreesia, Inc. has a 52-week low of $17.07 and a 52-week high of $30.53.

Phreesia (NYSE:PHR - Get Free Report) last released its earnings results on Monday, December 9th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.04. The company had revenue of $106.80 million during the quarter, compared to analysts' expectations of $106.33 million. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The business's revenue was up 16.6% on a year-over-year basis. During the same period in the prior year, the business posted ($0.58) EPS. Equities analysts anticipate that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Piper Sandler reissued an "overweight" rating and set a $33.00 target price (up previously from $31.00) on shares of Phreesia in a research report on Wednesday, January 29th. Needham & Company LLC restated a "buy" rating and issued a $29.00 price target on shares of Phreesia in a report on Friday, January 10th. Robert W. Baird decreased their price target on Phreesia from $34.00 to $30.00 and set an "outperform" rating for the company in a report on Wednesday, December 11th. Royal Bank of Canada upgraded Phreesia from a "sector perform" rating to an "outperform" rating and upped their price target for the stock from $24.00 to $32.00 in a report on Wednesday, January 8th. Finally, KeyCorp upped their price target on Phreesia from $28.00 to $30.00 and gave the stock an "overweight" rating in a report on Wednesday, January 8th. Thirteen investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $31.15.

Institutional Investors Weigh In On Phreesia

Institutional investors and hedge funds have recently made changes to their positions in the company. Versor Investments LP acquired a new stake in shares of Phreesia during the 3rd quarter valued at approximately $694,000. Zacks Investment Management acquired a new stake in shares of Phreesia during the 3rd quarter valued at approximately $631,000. State Street Corp raised its position in shares of Phreesia by 7.1% during the 3rd quarter. State Street Corp now owns 1,327,586 shares of the company's stock valued at $30,256,000 after acquiring an additional 88,517 shares in the last quarter. Wesbanco Bank Inc. raised its position in shares of Phreesia by 76.9% during the 4th quarter. Wesbanco Bank Inc. now owns 46,000 shares of the company's stock valued at $1,157,000 after acquiring an additional 20,000 shares in the last quarter. Finally, Barclays PLC raised its position in shares of Phreesia by 83.6% during the 3rd quarter. Barclays PLC now owns 94,929 shares of the company's stock valued at $2,163,000 after acquiring an additional 43,225 shares in the last quarter. 92.10% of the stock is owned by institutional investors and hedge funds.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.